Thermo Fisher Scientific Acquires TREK Diagnostic Systems
Wednesday, 20 July, 2011
Just when you thought Thermo Fisher was taking a rest from its recent acquisition frenzy... the company has announced today that it has acquired TREK Diagnostic Systems
The US-based TREK provides a platform of microbiology products, including blood culture, microorganism identification and antibiotic susceptibility testing (AST) products from Magellan Biosciences.
Based near Cleveland, Ohio, the company had full year revenue in 2010 of US$34 million and has 150 employees.
“The range of products manufactured by TREK ideally complements our existing portfolio of microbiological testing technologies,” said Marc N. Casper, President and Chief Executive Officer of Thermo Fisher Scientific.
“Advances in automation and the development of more rapid and reliable tests enable us to provide our customers with improvements in productivity and efficiency that are critical when responding to increasingly complex microbiological threats to human health.”
TREK Diagnostic Systems currently serves pharmaceutical and clinical laboratory markets and will be integrated into Thermo Fisher's Analytical Technologies Segment.
The University of Sydney formalises cervical cancer elimination partnership
The success of a cervical cancer elimination program has led to the signing of a memorandum of...
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
